{
  "pmcid": "10228712",
  "sha256": "06a5fd317f56f6d5850b41910a8601fe983af732397450ed8b3eec02e6cb8ed6",
  "timestamp_utc": "2025-11-09T23:04:21.610836+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 12.954666666666668,
    "reading_ease": 26.921777777777805,
    "word_count": 250
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Perioperative Outcomes of Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Non-Small Cell Lung Cancer: A Randomised Controlled Trial"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Forty-four patients with stage I-IIIA NSCLC were randomised"
      },
      "Participants": {
        "score": 1,
        "evidence": "patients with stage I-IIIA non-small cell lung cancer (NSCLC)"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomised to receive either N (3 mg/kg intravenously on days 1, 15, and 29; n = 23) or NI (N plus ipilimumab 1 mg/kg intravenously on day 1; n = 21)"
      },
      "Objective": {
        "score": 1,
        "evidence": "This randomised controlled trial evaluated the perioperative outcomes of neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI)"
      },
      "Method_Outcome": {
        "score": 1,
        "evidence": "The primary outcome was the rate of R0 resection, assessed at surgery."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, and allocation was concealed."
      },
      "Blinding": {
        "score": 0,
        "evidence": "Blinding was not applied."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Forty-four patients with stage I-IIIA NSCLC were randomised"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "The analysis was conducted per-protocol."
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "All 37 resected patients achieved R0 resection."
      },
      "Harms": {
        "score": 1,
        "evidence": "Complications included pulmonary (24%), cardiac (11%), enteric (5%), neurologic (3%), and wound (3%)."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration: [Trial registration number]."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: [Source of funding]."
      }
    },
    "total_score": 14,
    "max_score": 25
  }
}